Century Therapeutics (IPSC) Non-Current Deferred Tax Liability (2022 - 2026)

Century Therapeutics (IPSC) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $4.3 million in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $4.3 million, down 1.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (down 1.67% YoY), and the FY2025 annual result was $4.3 million, down 1.67% from the prior year.
• Non-Current Deferred Tax Liability held at $4.3 million in Q1 2026 per IPSC's latest filing, from $4.3 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $4.4 million in Q4 2024 and troughed at $5000.0 in Q4 2022.
• A 4-year average of $3.7 million and a median of $4.3 million in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 29.95% in 2025 and fell as far as 1.67% in 2025.
• A 4-year view of Non-Current Deferred Tax Liability shows it stood at $5000.0 in 2022, then jumped by 87380.0% to $4.4 million in 2024, then retreated by 1.67% to $4.3 million in 2025, then changed by 0.0% to $4.3 million in 2026.
• Business Quant data shows IPSC's Non-Current Deferred Tax Liability at $4.3 million in Q1 2026, $4.3 million in Q4 2025, and $4.4 million in Q3 2025.